8/103 sources · 2 publishersUpdated Oct 14, 22:09 UTC
Vanda Pharmaceuticals reports Phase III failure of VQW‑765 for social anxiety disorder
Vanda Pharmaceuticals announced that its Phase III study of VQW‑765 in adults with social anxiety disorder did not meet the primary or key secondary endpoints. The trial enrolled 546 participants and showed no statistically significant difference in distress scores between the drug and placebo. The company said the VQW‑765 program is on hold pending a full data analysis.
Why it matters
The failure caused Vanda’s shares to fall 6.2%. With the program placed on hold, the drug will not contribute to near‑term revenue or pipeline value until further data are reviewed.
Key facts
- 1The Phase III study randomized 546 adults aged 18 to 65 with social anxiety disorder. prnewswire.com
- 2In female participants, the mean Subjective Units of Distress Scale score was 65.6 for VQW‑765 versus 66.0 for placebo (p‑value 0.8899). investing.com
- 3In the full (male and female) population, the mean distress score was 64.7 for VQW‑765 versus 63.8 for placebo (p‑value 0.6605). investing.com
- 4The primary endpoint was not met; the drug did not show a statistically significant difference from placebo. prnewswire.com
- 5VQW‑765 was safe and well tolerated in the study. investing.com
- 6Vanda placed the VQW‑765 program on hold pending further analysis of the full dataset. prnewswire.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.